Skip to main content
Program

Women’s Brain Health

The cognitive changes women experience during perimenopause and menopause are not imagined, and they are not inevitable. They reflect measurable shifts in brain metabolism, hormonal signaling, and neuroinflammation—and they respond to targeted medical intervention.

Schedule a ConsultationCall (912) 268-3097

The Female Brain at Midlife

Estrogen is one of the most powerful neuroactive molecules in the human body. It regulates cerebral glucose metabolism, modulates synaptic plasticity, maintains mitochondrial function in neurons, and supports cerebral blood flow. When estrogen levels decline during the menopausal transition, the brain loses access to a primary metabolic regulator—and the consequences are not subtle.

Lisa Mosconi and colleagues, publishing in Neurology (2017), used PET and MRI imaging to demonstrate that perimenopausal women show significant reductions in cerebral glucose metabolism, increased amyloid-beta deposition, and decreased gray and white matter volume compared to premenopausal women of similar age. These are not changes that women imagine. They are measurable structural and functional alterations in the brain that correspond directly to the cognitive symptoms women report—difficulty concentrating, word-finding failures, short-term memory lapses, and a pervasive mental fatigue that sleep does not resolve.

Roberta Diaz Brinton, writing in Endocrine Reviews (2009), described the “estrogen paradox”—the observation that estrogen is neuroprotective throughout reproductive life but its withdrawal during menopause triggers a cascade of neuroinflammatory and metabolic changes that increase vulnerability to neurodegeneration. Her bioenergetic model shows that declining estrogen forces neurons to shift from efficient glucose-based metabolism to less efficient lipid metabolism, generating oxidative stress, mitochondrial dysfunction, and ultimately neuronal damage.

This is why women are twice as likely as men to develop Alzheimer’s disease—a disparity that longevity alone does not explain. The menopausal transition creates a window of neurological vulnerability that, without intervention, can accelerate the pathological processes underlying dementia.

What Standard Medicine Misses

Most women who report cognitive symptoms during perimenopause are told that what they’re experiencing is “normal aging” or “just stress.” Some are prescribed antidepressants. Others are referred for cognitive behavioral therapy. Very few receive the metabolic and neurological evaluation that would identify the correctable factors driving their symptoms.

A standard annual physical does not check inflammatory cytokines, homocysteine levels, vitamin D status, insulin sensitivity, or APOE genotype—all of which directly affect brain function and Alzheimer’s risk. Routine imaging protocols are designed to rule out tumors and stroke, not to evaluate regional cerebral metabolism or white matter connectivity.

The result is that women spend years managing symptoms with treatments that do not address the underlying neurobiology. Brain fog is treated as a mood disorder. Memory lapses are dismissed as benign. Sleep disruption is addressed with sedatives rather than metabolic correction. And the window during which targeted intervention could slow or prevent neurodegenerative changes narrows with each year of inaction.

Our Diagnostic Approach

The Women’s Brain Health Program at The Neurogenesis Project begins with a diagnostic evaluation designed to identify every correctable factor contributing to cognitive symptoms. We do not guess. We measure.

Dr. Orr conducts a comprehensive neurological examination and orders a full panel of labs specifically calibrated for women at midlife: estradiol, progesterone, FSH, LH, DHEA-S, total and free testosterone, and a complete thyroid panel including free T3, free T4, and thyroid antibodies. Beyond hormones, we evaluate inflammatory biomarkers (high-sensitivity CRP, IL-6, TNF-alpha), metabolic markers (homocysteine, folate, B12, vitamin D, magnesium, fasting insulin), and oxidative stress indicators.

APOE genotyping is included for every patient. Women who carry one or two copies of the APOE e4 allele face a significantly elevated lifetime risk of Alzheimer’s disease—and the menopausal metabolic shift appears to amplify that risk. Knowing a patient’s APOE status changes how aggressively we pursue metabolic optimization and how we prioritize long-term monitoring.

When clinically indicated, Dr. Orr orders advanced brain MRI using our NeuroCognitive protocol—sequences designed to evaluate hippocampal volume, white matter integrity, and structural changes that routine outpatient imaging does not assess. PET imaging may be added to map regional glucose metabolism and identify hypometabolic patterns consistent with early neurodegeneration. Cognitive testing establishes a quantitative baseline against which treatment response can be measured.

How We Treat This

Treatment protocols are assembled from diagnostic findings, targeting the specific metabolic, inflammatory, and mitochondrial deficits identified in each patient.

NAD+ IV Therapy

Restores the coenzyme critical to mitochondrial energy production and sirtuin-mediated DNA repair. Addresses the cellular energy deficit that estrogen withdrawal creates in neurons, supporting cognitive clarity and reducing neuronal oxidative stress.

Glutathione IV Therapy

The brain’s primary endogenous antioxidant. IV glutathione directly addresses the oxidative stress that accompanies the metabolic shift from glucose to lipid metabolism during menopause, protecting neurons from free radical damage.

Brain Health Lab Panels

Comprehensive metabolic, hormonal, inflammatory, and genetic testing calibrated for the female brain at midlife. Includes APOE genotyping, hormonal panels, and biomarkers that standard physicals do not evaluate.

NeuroCoaching

Dr. Edwards’ behavioral optimization program translates neurological findings into daily strategies for sleep, stress management, cognitive exercise, and nutritional choices that support brain health through the menopausal transition and beyond.

Advanced Neuroimaging

Brain MRI with NeuroCognitive protocol evaluates hippocampal volume and white matter integrity. PET imaging maps regional glucose metabolism to identify early hypometabolic patterns that structural MRI alone cannot detect.

Related Treatments

Alzheimer’s Prevention

Proactive neurological evaluation and intervention for patients at elevated risk of Alzheimer’s disease, including APOE e4 carriers and those with family history of dementia.

Brain Fog Treatment

Comprehensive neurological evaluation for persistent cognitive clouding, identifying metabolic, inflammatory, and hormonal factors that impair mental clarity and processing speed.

Sleep Disorders

Neurological evaluation and treatment for sleep disruption, a common and often undertreated contributor to cognitive decline during the menopausal transition.

Frequently Asked Questions

Why do so many women experience brain fog during perimenopause?+
Estrogen is not just a reproductive hormone. It is a primary regulator of cerebral glucose metabolism, synaptic plasticity, and mitochondrial function in the brain. During perimenopause, estrogen levels fluctuate unpredictably and then decline. This directly reduces the brain's ability to produce energy efficiently, maintain synaptic connections, and regulate neurotransmitter systems including acetylcholine, serotonin, and dopamine. The result is what women describe as brain fog: difficulty concentrating, word-finding problems, forgetfulness, and mental fatigue. These are not imagined symptoms. They reflect measurable changes in how the brain is functioning at a cellular level.
Is menopause-related cognitive decline the same as early Alzheimer's?+
Not necessarily, but the two are related in important ways. The cognitive changes of menopause are driven by hormonal shifts and are often reversible with appropriate metabolic intervention. However, research by Mosconi and colleagues has shown that the menopausal transition triggers biomarker changes in the brain — reduced glucose metabolism, increased amyloid deposition, and decreased gray matter volume — that overlap with early Alzheimer's pathology. Women who carry the APOE e4 allele are at particularly elevated risk. Our evaluation is designed to distinguish between reversible hormonal cognitive changes and early neurodegenerative processes, so that intervention can begin at the stage where it is most effective.
What does the Women's Brain Health evaluation include?+
We begin with a comprehensive neurological examination and detailed cognitive testing to establish baseline function. Lab work includes a full hormonal panel (estradiol, progesterone, FSH, LH, DHEA-S, testosterone, thyroid), inflammatory biomarkers (CRP, IL-6, TNF-alpha), metabolic markers (homocysteine, folate, B12, vitamin D, magnesium, insulin), and APOE genotyping to assess genetic Alzheimer's risk. When clinically indicated, Dr. Orr orders advanced brain MRI and PET imaging to evaluate structural integrity and metabolic activity. The goal is to identify every correctable factor contributing to cognitive symptoms before building a treatment plan.
Do you prescribe hormone replacement therapy?+
The Neurogenesis Project is a neurology practice, not an endocrinology or gynecology practice. We do not prescribe hormone replacement therapy directly. What we do is evaluate the neurological impact of hormonal changes and identify which metabolic, inflammatory, and mitochondrial deficits are contributing to your symptoms. We then treat those deficits with targeted interventions including NAD+ IV therapy, glutathione, and metabolic optimization protocols. We work alongside your OB-GYN or hormone specialist — our evaluation often provides the neurological data that helps those providers make better-informed decisions about hormonal management.
Why are women twice as likely to develop Alzheimer's disease?+
The disparity is not fully explained by longevity. Research from Brinton and Mosconi has demonstrated that the menopausal transition itself creates a window of neurological vulnerability. The decline in estrogen reduces cerebral glucose metabolism, compromises mitochondrial function, and triggers neuroinflammatory cascades that accelerate amyloid and tau accumulation. Women who carry the APOE e4 allele experience these changes more severely. Additionally, women have higher rates of conditions that independently increase Alzheimer's risk — autoimmune disorders, depression, sleep disruption, and chronic stress. Our program evaluates all of these factors together rather than treating them in isolation.
At what age should women start thinking about brain health?+
The research suggests that the perimenopause transition — which typically begins in a woman's early to mid-40s — is a critical intervention window. Mosconi's imaging studies show that brain metabolic changes begin during this period, often years before cognitive symptoms become noticeable. Women with a family history of Alzheimer's, those who carry the APOE e4 allele, or those experiencing early cognitive symptoms should consider evaluation sooner. However, there is no age at which brain health evaluation is premature. The earlier we establish a metabolic and cognitive baseline, the earlier we can identify and address correctable risk factors.

Your Brain Deserves More Than “It’s Just Menopause.”

The cognitive symptoms you are experiencing have a neurological basis, and they can be evaluated and treated. Dr. Orr and Dr. Edwards at The Neurogenesis Project are accepting new patients for Women’s Brain Health evaluations in St. Marys, Georgia.

Schedule Your Evaluation(912) 268-3097